7th European Stroke Conference, Edinburgh, May 29 1998: One year after CAPRIE, IST and ESPS2

Cerebrovascular Diseases

Volumn 8, Issue SUPPL. 5, 1998, Pages 1-7

  Hankey, Graeme J ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Antithrombotic therapy; Clinical trials; New concepts; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DANAPAROID; DIPYRIDAMOLE; FIBRIN; FIBRINOGEN RECEPTOR; HEPARIN; HEPARINOID; NADROPARIN; TICLOPIDINE;

BLEEDING; BRAIN ISCHEMIA; CONFERENCE PAPER; GASTROINTESTINAL HEMORRHAGE; HUMAN; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; RECURRENCE RISK; SECONDARY PREVENTION; SIDE EFFECT; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; TIME;

ANIMALS; CEREBROVASCULAR DISORDERS; HUMANS;

EID: 0031781971     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Sackett DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989;95:2S-4S.
2. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349: 1569-1581.
3. CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: A randomised placebo-controlled trial of early aspirin use in 20,000 patients with aucte ischaemic stroke. Lancet 1997;349:1641-1649.
4. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2. Dipyridamole and acetylsalicyclic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
5. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
6. Burn J, Dennis MS, Bamford J, Sandercock PAG, Wade D, Warlow CP: Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994;25:333-337.
7. Hankey GJ, Jamrozik KJ, Forbes S, Broadhurst R, Anderson C: Stroke recurrence over five years after first-ever stroke in Perth, Western Australia. Cerebrovasc Dis 1997;7(suppl 4):75.
8. Kay R, Wong KS, Yu YL, Chan YW, et al: Low-molecular-weight heparin for the treatment of acute ischaemic stroke. N Engl J Med 1995;333:1588-1593.
9. Bousser M: Aspirin or heparin immediately after a stroke? Lancet 1997;349:1564-1565.
10. TOAST Investigators: Usefulness of a low molecular weight heparinoid in improving outcomes at 7 days and 3 months after stroke: Results of the Trial of Org 10172 in Acute Stroke Treatment (TOAST) (abstract). Stroke 1998;29:286.
11. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
12. Algra A, van Gijn J: Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neural Neurosurg Psychiatry 1996;60:197-199.
13. Caplan LR: TIAs: We need to return to the question, 'What is wrong with Mr. Jones?' Neurology 1988;38:791-793.
14. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation and transient ischaemic attack or minor stroke. Lancet 1993;342: 1255-1262.
15. The Stroke Prevention in Reversible Ischaemia Trial (SPIRIT) Study Group: A randomized trial of anticoagulants versus aspirin after cerebral ischaemia of presumed arterial origin. Ann Neurol 1997;42:857-865.
16. Hankey GJ: Clopidogrel: A new, safe and effective antiplatelet agent. But unanswered questions remain. Med J Aust 1997;167:120-121.
17. van Gijn J, Algra A: Secondary stroke prevention with antithrombotic drugs: What to do next? Cerebrovasc Dis 1997;7(suppl 6):30-32.
18. Enserink M: Clinical trials: Fraud and ethics charges hit stroke drug trial. Science 1996;274: 2004-2005.
19. Dyken ML: Aspirin with and without dipyridamole. Cerebrovasc Dis 1997;7(suppl 6):10-16.
20. The SALT Collaborative Group: Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-1349.
21. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke. N Engl J Med 1991;325:1261-1266.
22. Lelorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F: Discrepancies between metaanalyses and subsequent large randomised, controlled trials. N Engl J Med 1997;337:536-542.
23. Lau J, Ioannidis SPA, Schmid CH: Summing up evidence: one answer is not always enough. Lancet 1998;351:123-127.
24. Uchiyama S, Sone R, Nagayama T, Shibagaki Y, Kobayashi I, Maruyama S, Kusakabe K: Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia. Stroke 1989;20:1643-1647.
25. DeCaterina R, Sicari R, Bernini W, Lazzerini G, Buti-Strata GB, Giannessi D: Benefit/risk profile of combined antiplatelet therapy with ticlopidine and aspirin. Thromb Haemost 1991;65:504-510.
26. Schomig A, Neumann F-J, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K: A randomised comparison of antiplatelet and anticoagulant therapy after placement of coronary artery stents. N Engl J Med 1996;334:1084-1089.
27. Bertrand M, Legrand V, Boland J, Fleck E, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L: Full anticoagulation versus ticlopidine plus aspirin after stent implantation: A randomised multicentre European study: The FANTASTIC trial (abstract). Circulation 1996;94(suppl 1):I-685.
28. Leong MB, Bairn DS, Gordon P, Giambartolomei A, Williams DO, Diver DD, Senerchia C, Fitzpatrick M, Popma JJ, Kuntz RE: Clinical and angiographic results from the STent Anticoagulation Regimen Study (STARS) (abstract). Circulation 1996;94(suppl 1):I-685.
29. Topol EJ: Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998;97:211-218.
30. Caplain H, D'Honneur G, Cariou R: Lack of interaction of aspirin (1,000 mg) with chronic clopidogrel in volunteers (abstract 557). Haemostasis 1996;26(suppl 3).
31. 3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-484.
32. PARAGON Investigators: A randomised trial of potent platelet IIb/IIIa antagonism, heparin or both in patients with unstable angina: The PARAGON Study. Circulation 1996;94:I-553.
33. Cannon CP, McCabe CH, Borzak A, et al, for the TIMI 12 Investigators: Randomised trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome. Circulation 1998;97:340-349.
34. Vorchheimer DA, Fuster V: Oral platelet glycoprotein IIb/IIIa receptor antagonists: The present challenge is safety. Circulation 1998; 97:312-314.
35. The Sixty Plus Reinfarction Study Research Group: A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the The Sixty Reinfarction Study Research Group. Lancet 1980;ii:989-994.
36. The EPSIM Research Group: A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-708.
37. Smith P, Arnesen H, Holme I: The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323: 147-152.
38. ASPECT Research Group: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet 1994;343: 499-503.
39. Campbell MH: Basilar artery syndrome. Can Med Assoc J 1953;69:314-315.
40. Hylek EM, Skates SJ, Sheehan MA, Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
41. Olsson JE, Brechter C, Backlund H, Krook H, Muller R, Nitelius E, Olsson O, Tornberg A: Anticoagulant vs. anti-platelet therapy as prophylaxis against cerebral infarction in transient ischaemic attacks. Stroke 1980;11:4-9.
42. Buren A, Ygge J: Treatment program and comparison between anticoagulants and platelet aggregation inhibitors after transient ischaemic attack. Stroke 1981;12:578-580.
43. Garde A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne LG, Ostman J: Treatment after transient ischaemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation. Stroke 1983;14:677-681.
44. WARSS Study Group: The feasability of a collaborative double-blind study using an anticoagulant. Cerebrovasc Dis 1997;7:100-112.
45. Hart RG, Boop BS, Anderson DC: Oral anticoagulants and intracranial haemorrhage: Facts and hypotheses. Stroke 1995;26:1471-1477.